Archive · 1 Oct 2026
Aurobindo Pharma’s A1 Labs Dilutes Stake After Gadikota Subscription
A1 Labs used to be fully owned by Apitoria Pharma.
Dr. Rajendra Gadikota bought new shares and debentures in A1 Labs.
His investment gives him a 20% stake when all possible conversions are counted.
Apitoria’s ownership consequently fell to 80%.
A1 Labs received a total of ₹33.80 crore from the transaction.
Gadikota is also a director of A1 Labs, so the deal is considered a related party transaction.
The company said the deal was conducted fairly and used a valuation prepared by a chartered accountant.
Shareholders approved the transaction through a special resolution.
A1 Biochem Labs (India) Private Limited is no longer wholly owned by Apitoria Pharma.
Dr. Rajendra Gadikota subscribed to shares and compulsory convertible debentures representing a 20% fully diluted stake.
Apitoria Pharma’s holding in A1 Labs fell from 100% to 80%.
A1 Labs received ₹9.18 crore for equity shares and ₹24.62 crore for debentures, totaling ₹33.80 crore.
The transaction was agreed on 23 July 2026 and completed on 30 September 2026 after shareholder approval.
- Who
- Aurobindo Pharma, its subsidiary Apitoria Pharma Private Limited, A1 Biochem Labs (India) Private Limited, and Dr. Rajendra Gadikota.
- What
- Gadikota acquired a 20% fully diluted stake in A1 Labs through equity shares and compulsory convertible debentures, reducing Apitoria’s holding to 80%.
- When
- The agreement was entered into on 23 July 2026, and the allotment was completed on 30 September 2026.
- Where
- The announcement was made from Mumbai; the articles do not specify where the transaction occurred.
- Why
- Gadikota subscribed to shares and debentures in A1 Labs; the articles do not state a separate business reason for the investment.
- Company affected
- A1 Biochem Labs (India) Private Limited, also referred to as A1 Labs
- Original owner
- Apitoria Pharma Private Limited initially held 100%
- New investor
- Dr. Rajendra Gadikota
- Gadikota’s stake
- 20% on a fully diluted basis
- Apitoria’s stake
- 80% after the allotment
- Total consideration
- ₹33.80 crore
- Shareholder approval
- Approved through a special resolution